Tag: cause

Platform Integration / Operational ExecutionOne year after acquiring Nautical Ventures, Vision Marine has advanced a broader marine platform combining premium retail distribution, marina operations,...

Addition of light data service further extends connectivity for Kyivstar customers, deepening customer engagement and reinforcing network resilience

Addition of light data service further extends connectivity for Kyivstar customers, deepening customer engagement and reinforcing network resilience

CHARLOTTE, N.C., June 16, 2026 /PRNewswire/ -- Greenland Mines Ltd ("Greenland Mines" or the "Company") (Nasdaq: GRML) is pleased to announce that it has...

INDIANAPOLIS, June 16, 2026 (GLOBE NEWSWIRE) -- Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored centers and vibrant mixed-use assets, today announced the completion of significant capital allocation activity, including the acquisition of two high-growth, open-air shopping centers, the disposition of six lower growth, non-core assets, and the execution of additional share buybacks.

NASDAQ: EUTSXV: EUwww.encoreuranium.comDALLAS, June 16, 2026 /PRNewswire/ - enCore Energy Corp. (NASDAQ: EU) (TSXV: EU) (the "Company" or "enCore"), America's Clean Energy CompanyTM, reports positive...

YY Group completes US$20 million ATM Program, raising approximately US$19.1 million net proceeds for AI, robotics and IFM initiatives.

Complementary upstream and downstream capabilities to enhance integration and enable the combined company to better create value across cycles, products and regions $400+ million...

TSX: TVECALGARY, AB, June 16, 2026 /CNW/ - Tamarack Valley Energy Ltd. has successfully closed the previously announced sale of its Charlie Lake assets for...

Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.

MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at...